cyclic cmp has been researched along with angiotensin ii in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gavini, N; Mandavia, CH; Pulakat, L | 1 |
| Borrajo, A; Diaz-Ruiz, C; Guerra, MJ; Labandeira-Garcia, JL; Rodriguez-Perez, AI | 1 |
| Carretero, OA; Garvin, JL; Ortiz, PA; Ramseyer, VD | 1 |
3 other study(ies) available for cyclic cmp and angiotensin ii
| Article | Year |
|---|---|
Role of Phe308 in the seventh transmembrane domain of the AT2 receptor in ligand binding and signaling.
Topics: Amino Acid Sequence; Angiotensin II; Animals; Cyclic CMP; Humans; Ligands; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes; Phenylalanine; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Rats; Receptor, Angiotensin, Type 2; Signal Transduction; Tyrosine; Xenopus | 2004 |
Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Cyclic CMP; Dopaminergic Neurons; Dose-Response Relationship, Drug; Enzyme Inhibitors; Kallikreins; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Neurons; Neurotoxins; Pancreatic Extracts; Tetrazoles; Tumor Necrosis Factor-alpha | 2014 |
Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs.
Topics: Angiotensin II; Animals; Cyclic CMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Endothelin-1; Hypertension; Loop of Henle; Male; Nitric Oxide; Nitric Oxide Donors; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Solute Carrier Family 12, Member 1; Vardenafil Dihydrochloride | 2016 |